Institute of Biomolecular Chemistry, National Council of Research, Pozzuoli (NA), Italy.
Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), 2725 Chemin Sainte-Foy, Québec, QC, G1V 4G5, Canada.
Curr Pharm Des. 2019;25(29):3147-3164. doi: 10.2174/1381612825666190826162735.
The Endocannabinoid (eCB) system and its role in many physiological and pathological conditions is well described and accepted, and includes cardiovascular disorders. However, the eCB system has been expanded to an "-ome"; the endocannabinoidome (eCBome) that includes endocannabinoid-related mediators, their protein targets and metabolic enzymes, many of which significantly impact upon cardiometabolic health. These recent discoveries are here summarized with a special focus on their potential involvement in atherosclerosis. We described the role of classical components of the eCB system (eCBs, CB1 and CB2 receptors) and eCB-related lipids, their regulatory enzymes and molecular targets in atherosclerosis. Furthermore, since increasing evidence points to significant cross-talk between the eCBome and the gut microbiome and the gut microbiome and atherosclerosis, we explore the possibility that a gut microbiome - eCBome axis has potential implications in atherosclerosis.
内源性大麻素（eCB）系统及其在许多生理和病理条件中的作用已得到很好的描述和认可，包括心血管疾病。然而，eCB 系统已经扩展到一个 "-ome"；内源性大麻素组（eCBome），其中包括内源性大麻素相关介质、它们的蛋白靶标和代谢酶，其中许多对心脏代谢健康有重大影响。本文总结了这些最近的发现，特别关注它们在动脉粥样硬化中的潜在作用。我们描述了经典内源性大麻素系统成分（eCBs、CB1 和 CB2 受体）和内源性大麻素相关脂质、其调节酶和分子靶标在动脉粥样硬化中的作用。此外，由于越来越多的证据表明 eCBome 与肠道微生物组以及肠道微生物组与动脉粥样硬化之间存在显著的串扰，我们探讨了肠道微生物组-eCBome 轴在动脉粥样硬化中的潜在意义的可能性。
